{
    "article_id": 1415,
    "public_id": "98aed495-849e-4dd9-9154-5ac335fa6f89",
    "internal_identifier": null,
    "source_identifier": "87:84",
    "status": "published",
    "type": "research_article",
    "title": "Retina ven tıkanıklığına bağlı maküla ödeminde intravitreal deksametazon tedavisinin etkinliği",
    "title_secondary": null,
    "abstract": "İntravitreal deksametazonun retina ven oklüzyonuna (RVO) bağlı maküla ödeminde (MÖ) etkinliğini değerlendirmek. Material metot: Retrospektif yapılan bu çalışmaya RVO’ya bağlı MÖ olan 11 naiv hasta dahil edildi. Hastalara tek doz intravitreal deksametzon implant tedavisi yapıldı. Hastalar ilk ay içinde haftada bir, sonraki aylarda ise ayda bir görüldüler. Hastaların en iyi düzeltilmiş görme keskinlikleri (EİDGK) ve optik koherans tomografi cihazı ile alınan santral maküla kalınlık (SMK) ölçümleri değerlendirildi. Sonuçlar:  Tek doz deksametazon tedavisi  ile EİDGK’de (1.30 ± 0.59 to 0.89 ± 0.51 logMAR) artış  ve SMK’da (743 ± 160 μm to 464 ± 213 μm) azalma 3 ay boyunca devam etti (p <0.001). Tedaviden 14 hafta sonra EİDGK (0.90 ± 0.44 logMAR) azaldı ve SMK da ise artış (579 ± 107 μm, p >0.05) görüldü.  Tartışma: Tek doz deksametazon implant  tedavisi RVO’ya bağlı MÖ’inde  14 hafta boyunca etkinliğini sürdürmektedir.",
    "language": "tr",
    "english_title": "Efficacy of Intravitreal Dexamethasone Treatment in Macular Edema Due to Retinal Vein Occlusion",
    "english_abstract": "To evaluate the efficacy of intravitreal dexamethasone in macular edema (ME) due to retinal vein occlusion (RVO). Material and methods: This retrospective study included 11 naive patients with ME due to RVO. Patients received a single dose of intravitreal dexamethasone implant treatment. Patients were seen weekly during the first month and monthly in subsequent months. Best corrected visual acuity (BCVA) and central macular thickness (CMT) measurements obtained with optical coherence tomography were evaluated. Results: With a single dose of dexamethasone, an increase in EIDGC (1.30 ± 0.59 to 0.89 ± 0.51 logMAR) and a decrease in CMT (743 ± 160 μm to 464 ± 213 μm) persisted for 3 months (p <0.001). Fourteen weeks after treatment, EIDGC decreased (0.90 ± 0.44 logMAR) and CMT increased (579 ± 107 μm, p >0.05). Discussion: Single-dose dexamethasone implant treatment maintains efficacy for 14 weeks in RVO-related myocardial infarction (MI).",
    "doi": "10.36287/setsci.4.9.084",
    "doi_url": "https://doi.org/10.36287/setsci.4.9.084",
    "resource_url": "https://www.set-science.com/a/98aed495-849e-4dd9-9154-5ac335fa6f89",
    "pdf_url": "https://www.set-science.com/a/98aed495-849e-4dd9-9154-5ac335fa6f89/pdf",
    "og_image": "https://www.set-science.com/assets/img/og-card-v2.png",
    "authors": [
        {
            "public_id": "a5e1f294-675a-470f-a1b0-e696a42682c5",
            "given": "Tayfun",
            "family": "Şahin",
            "full": "Tayfun Şahin",
            "literal": null,
            "orcid": null,
            "orcid_url": null,
            "email": "drtayfunsahin82@gmail.com",
            "corresponding": true,
            "sequence": "first",
            "affiliations": [
                {
                    "name": "Hitit University",
                    "department": null,
                    "country": null,
                    "country_code": null,
                    "ror": null,
                    "ror_url": null
                }
            ]
        }
    ],
    "keywords": [],
    "translations": [
        {
            "language": "en",
            "title": "Efficacy of Intravitreal Dexamethasone Treatment in Macular Edema Due to Retinal Vein Occlusion",
            "abstract": "To evaluate the efficacy of intravitreal dexamethasone in macular edema (ME) due to retinal vein occlusion (RVO). Material and methods: This retrospective study included 11 naive patients with ME due to RVO. Patients received a single dose of intravitreal dexamethasone implant treatment. Patients were seen weekly during the first month and monthly in subsequent months. Best corrected visual acuity (BCVA) and central macular thickness (CMT) measurements obtained with optical coherence tomography were evaluated. Results: With a single dose of dexamethasone, an increase in EIDGC (1.30 ± 0.59 to 0.89 ± 0.51 logMAR) and a decrease in CMT (743 ± 160 μm to 464 ± 213 μm) persisted for 3 months (p <0.001). Fourteen weeks after treatment, EIDGC decreased (0.90 ± 0.44 logMAR) and CMT increased (579 ± 107 μm, p >0.05). Discussion: Single-dose dexamethasone implant treatment maintains efficacy for 14 weeks in RVO-related myocardial infarction (MI).",
            "keywords": [
                "Intravitreal deksametazon, maküler ödem, retina ven oklüzyonu"
            ]
        }
    ],
    "subjects": [],
    "subject_names": [],
    "published_date": "2019-12-23",
    "published_year": "2019",
    "received_date": null,
    "accepted_date": null,
    "volume": "12",
    "issue": null,
    "page_first": "146",
    "page_last": "150",
    "article_number": null,
    "conference": {
        "short_name": "ISAS WINTER-2019 (HSS)",
        "full_title": "4th International Symposium on Innovative Approaches in Health and Sports Sciences",
        "name": "4th International Symposium on Innovative Approaches in Health and Sports Sciences",
        "acronym": "ISAS WINTER-2019 (HSS)",
        "location": "Samsun, Türkiye",
        "start_date": "2019-11-22",
        "end_date": null,
        "public_id": "76ee0eb0-7f71-420c-9d1c-2b81a3a76e96"
    },
    "proceedings": {
        "title": "4th International Symposium on Innovative Approaches in Health and Sports Sciences",
        "series_title": "SETSCI Conference Proceedings",
        "publisher": "SET Technology",
        "isbn": "978-605-81988-9-0",
        "eisbn": null,
        "issn": null,
        "eissn": "2687-5527",
        "doi": null,
        "doi_prefix": "10.36287",
        "slug": "setsci-volume-12-2019-legacy-87",
        "public_id": "083b6600-6489-43ad-9a7d-d9fd7505e910",
        "url": "https://www.set-science.com/p/setsci-volume-12-2019-legacy-87"
    },
    "license": {
        "name": "CC BY 4.0",
        "url": "https://creativecommons.org/licenses/by/4.0/",
        "code": "CC-BY-4.0",
        "open_access": true
    },
    "copyright": {
        "holder": "SET Technology",
        "year": "2019"
    },
    "funding_statement": null,
    "funders": [],
    "references": [
        {
            "order": 1,
            "raw": "1. Ho M, Liu DT, Lam DS, Jonas JB. Retinal vein occlusions, from basics to the latest treatment. Retina. 2016; 36:432–448.\r\n2. Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, Kowalski JW, Nguyen H, Wong TY: The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117: 313–319.\r\n3. Wong TY., Scott IU. Clinicalpractice. Retinal-vein occlusion. N. Engl J. Med 2010; 363:2135-2144. \r\n4. Campochiaro PA., Bhisitkul RB., Shapiro H., Rubio RG. Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology.2013;120:795-802.\r\n5. Felinski EA, Antonetti DA. Glucocorticoid regulation of endothelial cell tight junction gene expression: novel treatments for diabetic retinopathy. Curr Eye Res. 2005;30:949–957.\r\n6. Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol. 1998;341:309–315.\r\n7. Ashraf M, Souka AAR: Steroids in central retinal vein occlusion: is there a role in current treatment practice? J Ophthalmol. 2015; 2015: 594615.\r\n8. Yoshimura T, Sonoda KH, Sugahara M et al. Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. PLoS One 2009;4:e8158.\r\n9. Haller JA, Bandello F, Belfort R Jr, Ozurdex GENEVA Study Group et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion. Twelve-month study results. Ophthalmology. 2011;118:2453–2460.\r\n10. Chang-Lin JE, Attar M, Acheampong AA et al. Pharmacokinetics and pharmacodynamics of a sustained release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011;52:80–86.\r\n11. Manousaridis K, Peter S, Mennel S. Outcome of intravitreal dexamethasone implant for the treatment of ranibizumab-resistant macular edema secondary to retinal vein occlusion. Int Ophthalmol. 2017;37:47-53.\r\n12. Michalska-Małecka K, Gaborek A, Nowak M, Halat T, Pawłowska M, Śpiewak D. Clin Interv Aging. 2016;11:699-705.\r\n13. Joshi L, Yaganti S, Gemenetzi M, Lightman S, Lindfield D, Liolios V, Menezo V, Shao E, Taylor SR. Dexamethasone implants in retinal vein occlusion: 12-month clinical effectiveness using repeat injections as-needed. Br J Ophthalmol. 2013;97:1040–1044.\r\n14. Yucel OE, Birinci H, Sullu Y. The short-term efficacy of intravitreal ranibizumab, aflibercept and dexamethasone implant in the treatment of macular edema due to non-ischemic central retinal vein occlusion. Int Ophthalmol. 2019;39:891-901.",
            "doi": null,
            "title": null,
            "authors": null,
            "source": null,
            "year": null,
            "volume": null,
            "pages": null
        }
    ],
    "statements": {
        "acknowledgements": null,
        "conflict_of_interest": null,
        "data_availability": null,
        "ai_disclosure": null
    },
    "credit": [],
    "history": {
        "published": "2019-12-23"
    }
}